{"name":"Bioblast Pharma Ltd.","slug":"bioblast-pharma-ltd","ticker":"","exchange":"","domain":"","description":"Bioblast Pharma Ltd. is a biotechnology company focused on developing treatments for rare and orphan diseases. The company has a pipeline of five drugs in various stages of clinical development, with a strong emphasis on innovative therapies.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Cabaletta","genericName":"Cabaletta","slug":"cabaletta","indication":"Other","status":"phase_2"},{"name":"Tehalose 30gr","genericName":"Tehalose 30gr","slug":"tehalose-30gr","indication":"Stabilizer in various pharmaceutical formulations","status":"phase_3"},{"name":"Trehalose for IV Infusion","genericName":"Trehalose for IV Infusion","slug":"trehalose-for-iv-infusion","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Cabaletta","genericName":"Cabaletta","slug":"cabaletta","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tehalose 30gr","genericName":"Tehalose 30gr","slug":"tehalose-30gr","phase":"phase_3","mechanism":"Tehalose is an excipient used as a stabilizer in pharmaceutical formulations.","indications":["Stabilizer in various pharmaceutical formulations"],"catalyst":""},{"name":"Trehalose for IV Infusion","genericName":"Trehalose for IV Infusion","slug":"trehalose-for-iv-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNdzdFRE9UOHh0aUdfUWdIazI4OVQ0S0ZJdFAwYW9Nd2s4aWhTRGdYRFlTVkIyUE1RVS1fQ3pwQ2ZtclVyU2huY0RxejNhYTIyVjg1ZFZ1VjN3NUhtcmVqVGtobDlobVZhWDZvdGRPcElkNFZsclBydWw2QU1TWWVGeUlWMFdsMG11cmNQeUtDMEZqU3M4NDk4?oc=5","date":"2026-03-03","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the week ending 27 February 2026 - Pearce IP","headline":"Pearce IP BioBlast® for the week ending 27 February 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMFA4bUxxc0cwVnk1VnNILTZJSmhIQUpaYm9ocWJyZ2gyMUtDeUFOaGZrdkF4Zmw2Qk9Kc3IzTDdad0poVE9OMFczRm83eHZxaFRlWXdsT3pzSERXUElpVGtTekdITnJZTUUzbFBzLWFSS2d4cUt3dndVWjRNMUlXVTZxb3NCTTlyWDd5ZGVrSElZZTg1MnE4?oc=5","date":"2026-02-17","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the week ending 13 February 2026 - Pearce IP","headline":"Pearce IP BioBlast® for the week ending 13 February 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNclVGWDNiWl9xY0xQa2RXTWo0X2NhT1ZBLV9xZk9HeDBUamx2a25VV1FwNWdBNGtuZXp6cHoxWUlLUThVQjB3M0YwaWk3dkxlTE4ycmlRNkRxenBwa2dDRDViQWhQXzNiQlZMOEtoeXVUTlhVR0c1Y0F1d0RmZFY5U18yR0l2eFFfY3RPcTJ6aHNLRllueHc?oc=5","date":"2026-02-03","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the week ending 30 January 2026 - Pearce IP","headline":"Pearce IP BioBlast® for the week ending 30 January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQNWhnM1BXQ3RPQXJNMkJMdjEwaGs1b0h1eGJSeDE2UXdvUWZuNFZsanVEY2t1endMOXE1NFkwQzh3V3lPaDBzbDNDcEY5cFdtNTIyR0VrQkVkZVU2VmljemtyZHhqV2xoRGZSLWo3Z0tRNG9zUmVlRzMzZl9aSFNaSUNJMU5kclN6NElPQjVjSW5maFFfYXc?oc=5","date":"2026-01-20","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the week ending 16 January 2026 - Pearce IP","headline":"Pearce IP BioBlast® for the week ending 16 January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVUMwaVRicFF0RUNPWHcxaElyUUJlakljWm5nX3lEZDVZMUVkaWlVbEdkXzVqLVBXWTItRlNIcjZFd0ViS0o2cnpRalIzSnJfeC1TaHVmZ0llcmZtUWxYOEhienNFTFdxZ0VqalB5ZW1EdHR1MmthUW9qcXI2SFRyMm85NFVaRXBKV1B0REY1Z3haN2FuVVJRYmUzTjd5QV9feDd6dg?oc=5","date":"2026-01-13","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the last three weeks ending 9 January 2026 - Pearce IP","headline":"Pearce IP BioBlast® for the last three weeks ending 9 January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5vWHhveFE0WEtXa1lucFR4YTEtYmJxQ1Jqc0lQRk1RWktSZEZ0eWdSUDFxSkZMcnVVS3gzUkpXQkU4cjRzWXhyTk9FZ3VtM0FFd2lNUFAtTkxBN2R4WFRIZHVmOEdFMzQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Market.us","summary":"Intravenous Pegloticase Market Size, Share | CAGR of 13.8% - Market.us","headline":"Intravenous Pegloticase Market Size, Share | CAGR of 13.8%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNNmFDVVl6LTBhdHJyZmtkcUtMZGNqUG4zRVRHYW5VLWNURTdNLVllQ2FFc3lUZURGa21zeWdaSzhsTlRxa3FSTWpRU19XNF94MVJYSnd3RmRvVFRpX1hyNGlBR2N6QVR2R2F2WjFDUGxwNGoyemNtcmN2WWJRMjNSTFRsek5LUE5MN3Z4WmlDWVd0eHFnZFE?oc=5","date":"2025-12-09","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the week ending 5 December 2025 - Pearce IP","headline":"Pearce IP BioBlast® for the week ending 5 December 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOaDEyNlg1Zmx2ZGFYZGV3Tnd2ZHo1a1BBLXd4Mi1vRzh2dW9udFZMdHJOLTRaNmtURm1kSUhtSThtSlpJb0lMZ2h6NXF2eUZIMl90cUJZSWNfT2dzQ242RC1wbW5MMm1WV3NyUGdMdVZGaWxiV0JSUk5BcW5janRjalo4b3ZsTTBHQVhuVmdaQU9wVkFp?oc=5","date":"2025-11-28","type":"pipeline","source":"Research Nester","summary":"Oculopharyngeal Muscular Dystrophy Market Size & Share, Growth Forecasts 2035 - Research Nester","headline":"Oculopharyngeal Muscular Dystrophy Market Size & Share, Growth Forecasts 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPZFhYaTJJNndjTXdyalJ3X1ZlSndIM0R1MFJ1d3pfZ3lTcDdtVUNNdjBIc3RFWUlETlJzY0owZFNpbk9HZ096MVB6X2hGYUhlQVBfenFrYUxJT2ZnOWotRmppdHpVelk0RGJFRUxUX3JZWnpESmFzTEMta01Jb29jNE9fZVRlZmFzZkVyTDVWWGFKaTUyUU1EZXJYd1NXYzA?oc=5","date":"2025-09-16","type":"pipeline","source":"Pearce IP","summary":"Pearce IP BioBlast® for the fortnight ending 12 September 2025 - Pearce IP","headline":"Pearce IP BioBlast® for the fortnight ending 12 September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNFVVejlNTExHbmxaTmJmMU52NkRvNnhFWTYtTGhHTkEyT1dNR0ZMVnlKTTFwYWFDUlZuaGp5bHBtdGVsVFVaVDJtR0liOW5EN3l0bjQ4QjRxTDY5bFdhSXhJYWF0VFZfeXlOX014TmJ0cEh6M3NydjJTV0EtYklOeVhxc01LcGh3Rmw5emZ3V0lhVURzV0FLVjhNRWNpQ2YtcTJlLUcwNUZXdw?oc=5","date":"2020-10-01","type":"pipeline","source":"The Jerusalem Post","summary":"Israeli pharma pioneer introduces TaffiX antiviral nose-powder - The Jerusalem Post","headline":"Israeli pharma pioneer introduces TaffiX antiviral nose-powder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTk1JWk5rR1c3clM5UFZuYlpIdHVMNHJ6WnBkOUREc2p2TmJWc3Rlek9yaTUxNnE2WE5Icm9nMHFiSFN0YXgxV1d6THJRZzR2RGZGa3BJUTJmYlZqRFdOeGdaWk1mdkgyY3J5X3NkaFcyMnVBNXdmRE1YUlpTVmRid0VJeWNLSjZPZ05UTk5XSzQ3dTRLWTNGN0N4X3k4Vklka3E4?oc=5","date":"2015-10-29","type":"trial","source":"Muscular Dystrophy News","summary":"OMD Patients Show ‘Very Encouraging’ Results in Phase 2 Study of Cabaletta - Muscular Dystrophy News","headline":"OMD Patients Show ‘Very Encouraging’ Results in Phase 2 Study of Cabaletta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNcmpPaVJFcksxeGtZeDA5OFVQN25sQmVKeFBsOVd4WkFpVWhiWmhVb1gzWEdndmRqd3poMFBTUXBscDNBbnpyWHVWSk1qdU9GMU56aXYzNi1KME1pUVZHNnhLZ09jTnZZQkg4UzNoWFdXOExZQnBYR0xGMWR4aHdnbXBWZGhOczdNeTVYcnZESDZLMW4yRXlqZm01ZjVVcnhnU0Z6UHdJVVg2dFNleWRpc05zeFRPc1FDSUVDM3BpQQ?oc=5","date":"2015-06-23","type":"trial","source":"Muscular Dystrophy News","summary":"BioBlast Starts Phase 3 Trial For Cabaletta Therapy in... - Muscular Dystrophy News","headline":"BioBlast Starts Phase 3 Trial For Cabaletta Therapy in...","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}